Physician profile
Brandon Miller
NPI 1760007173
$863.39
in general payments reported to CMS, 2019-2025
14 companies · $241 in 2025
The $241 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $68.46 · 2024: $553 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $863.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $863.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $183.14 | 2024-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $149.27 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $102.86 | 2024 | Tezspire, Fasenra |
| United Therapeutics Corporation | $75.28 | 2024-2025 | Tyvaso, Remodulin |
| Baxter Healthcare | $64.87 | 2023-2024 | Hillrom - Vest System Model 105 Home Care |
| Regeneron Healthcare Solutions, INC. | $58.62 | 2024 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $45.38 | 2024-2025 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.68 | 2024 | Ofev |
| Sandoz INC. | $28.29 | 2024 | Treprostinil |
| Mylan Specialty L.P. | $27.86 | 2024 | Yupelri |
| Glaxosmithkline, LLC. | $22.92 | 2025 | Trelegy Ellipta |
| Abiomed | $22.91 | 2025 | |
| Aimmune Therapeutics, INC. | $21.49 | 2024 | |
| Alexion Pharmaceuticals, INC. | $15.82 | 2023 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.